Deadline to submit expressions of interest to represent civil society at PRAC andCAT to European Commission extended until 18 October
LONDON, 1-10-2015 — /EuropaWire/ — The Health and Food Safety Directorate-General of the European Commission has extended the deadline for its calls for expressions of interest to represent civil society in two scientific committees of the European Medicines Agency (EMA): the Pharmacovigilance Risk Assessment Committee (PRAC) and the Committee for Advanced Therapies (CAT).
For both calls, expressions of interest should be submitted to the European Commission no later than 18 October 2015, either by email or post. Further information on the assessment criteria and the application process can be found on the Commission’s website.
The PRAC has one member and one alternate representing patients’ organisations as well as one member and one alternate representing healthcare professionals’ organisations. The term of office of the current members expires on 29 February 2016. The new civil society members will be appointed for a three-year period.
The CAT has two members and two alternates representing patients’ organisations and two members and two alternates representing clinicians, and the term of office of the current members expires on 30 June 2016. The new members will be appointed for a renewable period of three years.
The role of patients’ and healthcare-professionals’ organisations representatives in the CAT and PRAC is to ensure that the needs and views of the groups they represent as well as the real-life implications of any committee recommendations, are taken into account during the discussions of the committees.
Appointees will be involved in the committees’ work in the same way as other committee members. They are expected to attend the monthly committee meetings at EMA and to actively contribute to scientific discussions, examine documents and make comments with a specific focus on the group that they represent.
The European Commission will appoint the civil society members after consultation with the European Parliament.
About EMA committees
PRAC has a key role in overseeing the safety of medicines in the European Union. The committee’s activities cover all aspects of the safety monitoring and risk management of medicines.
CAT is responsible for assessing the quality, safety and efficacy of advanced-therapy medicinal products (ATMPs) and following scientific developments in the field. ATMPs are medicines that are derived from gene therapy, cell therapy or tissue engineering.
PRAC and CAT have one member and alternate per Member State and the PRACalso has six scientific experts appointed by the European Commission. In addition, these committees include representatives of healthcare-professional and patient organisations, as foreseen by the European pharmaceutical legislation (Regulation (EU) No 1235/2010 and Regulation (EC) No 1394/2007 on advanced therapy medicinal products). This is also the case for two other scientific committees of the Agency, the Paediatric Committee (PDCO) and the Committee for Orphan Medicinal Products (COMP).
PRESS OFFICE CONTACT
Head of press office
30 Churchill Place
London E14 5EU
Tel. +44 (0)20 3660 8427